CytomX Therapeutics, Inc. CTMX
We are a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet need in oncology. CytomX has led the field of conditionally activated, masked biologics through the development of its PROBODY technology platform. This versatile, multi-modality platform is built on a strong foundation of tumor biology expertise, including deep knowledge of tumor-associated enzymes known as proteases. Our masking strategy is designed to reduce binding of biologic therapeutics to their targets until the mask is removed by proteases in the tumor microenvironment, providing more selective targeting of the tumor and optimizing the predicted therapeutic index of our clinical candidates.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76.2M | $138.1M | $101.2M | $53.2M | $37.3M | $68.4M | $26.9M | $59.5M | $71.6M | $12.8M |
| R&D | $68.7M | $83.4M | $77.7M | $111.6M | $114.2M | $112.9M | $131.6M | $103.9M | $92.3M | $54.8M |
| SG&A | $29.8M | $29.7M | $30.0M | $42.8M | $39.2M | $36.0M | $36.8M | $33.5M | $25.6M | $19.9M |
| Total operating expenses | $98.6M | $113.1M | $107.7M | $154.5M | $153.4M | $149.0M | $168.4M | $137.4M | $117.9M | $74.6M |
| Operating income | -$22.4M | $25.0M | -$6.5M | -$101.3M | -$116.0M | -$80.5M | -$141.5M | -$77.9M | -$46.3M | -$59.6M |
| Interest expense | — | — | — | — | — | — | — | — | — | $1.7M |
| Pre-tax income | -$17.1M | $32.1M | $3.3M | -$99.3M | -$115.9M | -$78.7M | -$133.3M | -$70.3M | -$43.6M | -$58.9M |
| Income tax | $238.0K | $224.0K | $3.9M | $0 | $0 | $13.9M | $427.0K | $14.3M | $513.0K | $19.0K |
| Net income | -$17.4M | $31.9M | -$569.0K | -$99.3M | -$115.9M | -$64.8M | -$132.8M | -$84.6M | -$43.1M | -$58.9M |
| EPS, diluted | — | — | — | — | — | — | — | — | -1.16 | -1.63 |
| Shares, diluted (wtd. avg.) | $137.9M | $84.7M | $73.8M | $65.7M | $64.1M | $46.1M | $45.3M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $12.7M | $38.1M | $17.2M | $193.7M | $205.5M | $191.9M | $188.4M | $247.6M | $177.5M | $105.6M |
| Short-term investments | $124.4M | $62.6M | $157.3M | $0 | $99.7M | $124.3M | $107.7M | $188.6M | $196.6M | — |
| Receivables | $2.0M | $3.1M | $3.4M | $36.0M | $790.0K | $798.0K | $13.0K | $97.0K | $10.1M | $2.2M |
| Total current assets | $143.9M | $107.3M | $182.9M | $237.1M | $310.3M | $324.0M | $303.3M | $445.5M | $388.6M | $188.1M |
| Property, plant and equipment | $1.3M | $2.5M | $4.0M | $5.1M | $6.0M | $7.0M | $7.4M | $6.9M | $4.2M | $4.4M |
| Goodwill | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K |
| Total assets | $151.6M | $120.5M | $201.8M | $260.9M | $339.4M | $358.7M | $341.3M | $457.1M | $397.6M | $199.1M |
| Accounts payable | $1.3M | $1.1M | $1.5M | $2.8M | $2.8M | $3.0M | $4.2M | $5.1M | $4.2M | $6.6M |
| Total current liabilities | $46.6M | $85.8M | $155.9M | $152.6M | $60.3M | $68.1M | $85.6M | $97.9M | $61.1M | $35.8M |
| Total liabilities | $52.6M | $121.0M | $249.2M | $346.6M | $344.3M | $366.4M | $290.2M | $326.2M | $327.7M | $120.6M |
| Retained earnings | -$711.9M | -$691.6M | -$723.4M | -$722.9M | -$557.8M | -$507.7M | -$442.9M | -$315.0M | -$219.5M | -$176.4M |
| Total equity | $99.0M | -$456.0K | -$47.4M | -$85.8M | -$459.0K | -$7.8M | $25.5M | $135.8M | $69.9M | $78.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$75.6M | -$86.2M | -$56.0M | -$110.8M | -$119.0M | $5.3M | -$140.5M | -$75.5M | $170.4M | -$2.0M |
| Depreciation and amortisation | $1.2M | $1.6M | $2.0M | $2.3M | $2.6M | $2.4M | $2.5M | $1.7M | $1.5M | $1.7M |
| Stock-based compensation | $6.3M | $7.7M | $8.6M | $13.1M | $13.2M | $14.8M | $19.1M | $16.9M | $11.3M | $10.1M |
| Capital expenditure | $220.0K | $310.0K | $840.0K | $1.7M | $1.6M | $2.3M | $3.5M | $3.8M | $1.6M | $2.2M |
| Investing cash flow | -$59.7M | $99.7M | -$150.7M | $98.3M | $22.5M | -$18.7M | $79.7M | $5.9M | -$121.3M | $45.9M |
| Financing cash flow | $110.4M | $7.5M | $30.2M | $648.0K | $110.2M | $16.9M | $1.6M | $139.6M | $23.8M | $996.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-107146.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |